ArticleThe EMBO journal1997
Using altered specificity Oct-1 and Oct-2 mutants to analyze the regulation of immunoglobulin gene transcription.
Article in The EMBO journal, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 63 citations in OpenAlex.
- An atlas of cells in the human tonsil.Immunity · 2024Article
- Metabolic and Biomolecular Changes Induced by Incremental Long-Term Training in Young Thoroughbred Racehorses during First Workout Season.Animals : an open access journal from MDPI · 2020Article
- Article
- Tailoring the models of transcription.International journal of molecular sciences · 2013Review
- Epstein-Barr virus latency switch in human B-cells: a physico-chemical model.BMC systems biology · 2007Article
- A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory.The EMBO journal · 2006Article
- Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression.The Biochemical journal · 2005Article
- Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein.Molecular and cellular biology · 2005Article
- Use of altered-specificity binding Oct-4 suggests an absence of pluripotent cell-specific cofactor usage.Nucleic acids research · 2005Article
- C/EBPbeta regulation in lipopolysaccharide-stimulated macrophages.Molecular and cellular biology · 2003Article
- Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms.The American journal of pathology · 2003Article
- Oct-2 regulates CD36 gene expression via a consensus octamer, which excludes the co-activator OBF-1.Nucleic acids research · 2002Article
- Mouse lymphoid cell line selected to have high immunoglobulin promoter activity.Molecular and cellular biology · 2002Article
- Subclass-specific nuclear localization of a novel CD4 silencer binding factor.The Journal of experimental medicine · 1999Article
- B-Cell coactivator OBF-1 exhibits unusual transcriptional properties and functions in a DNA-bound Oct-1-dependent fashion.Molecular and cellular biology · 1999Article
- Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.The EMBO journal · 1999Article
- [Molecular-genetic mechanisms of developing the brain based on an embryonic Xenopus model].Molekuliarnaia biologiiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Oct-1 and Oct-2 represent the prototypical example of related transcription factors with identical DNA recognition properties. They bind functionally critical octamer elements found in diverse regulatory sequences. It has not been possible to determine directly if these factors are functionally redundant or selective when interacting with different regulatory sequences in the appropriate cell type. An equivalent pair of altered DNA-binding specificity mutants of Oct-1 and Oct-2 are used to examine their function from varied regulatory contexts in B cells. These factors function as redundant activators of immunoglobulin (Ig) gene promoters (Vkappa and VH) and a histone H2B promoter. The structural basis of redundancy resides in the highly conserved DNA-binding POU domain, because this domain of either protein can activate transcription from both Ig and H2B promoters. We find that the nature of a distal enhancer dictates the relative potency of Oct-1 versus Oct-2 bound to a promoter. Oct-1 preferentially stimulates transcription from a VH or Vkappa promoter in combination with enhancers from the IgH or Igkappa locus, respectively. In this context, the more potent action of Oct-1 is dependent on a region external to the POU domain. These results suggest that Oct-1 may be the critical regulator of Ig gene transcription during B cell development and provide an explanation for selective Ig isotype expression defects in Oct-2 and OCA-B null mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.